Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Douglas Fraser-Pitt"'
Autor:
Graham Devereux, Douglas Fraser-Pitt, Jennifer Robertson, Edward Devlin, Derry Mercer, Deborah O'Neil
Publikováno v:
EBioMedicine, Vol 2, Iss 10, Pp 1507-1512 (2015)
Background: Cysteamine has recently been shown to have in vitro properties potentially therapeutically beneficial in cystic fibrosis (CF). In this study we investigated the antimicrobial and mucolytic activity of cysteamine against the complex biolog
Externí odkaz:
https://doaj.org/article/6f88c9b4b92240dd9cd82dd58a70c85d
Publikováno v:
Antimicrobial Agents and Chemotherapy
There are no wholly successful chemotherapeutic strategies against Burkholderia cepacia complex (BCC) colonization in cystic fibrosis (CF). We assessed the impact of cysteamine (Lynovex) in combination with standard-of-care CF antibiotics in vitro ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49402eb854aef46a3b30828097113d7
https://doi.org/10.1128/aac.01198-16
https://doi.org/10.1128/aac.01198-16
Autor:
Aleksandra Kowalczuk, Michelle J Cole, Michel Doumith, Neil Woodford, Emma Lovie, Peter Perenyi, Jennifer M. Robertson, Douglas Fraser-Pitt, Deborah O'neil, Derry K. Mercer, Katie L. Hopkins, Daniel J. Smith, Robert Hill
Publikováno v:
Infection and Immunity
Cysteamine is an endogenous aminothiol produced in mammalian cells as a consequence of coenzyme A metabolism through the activity of the vanin family of pantetheinase ectoenzymes. It is known to have a biological role in oxidative stress, inflammatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93cdeba92576e4cd0efbcba84845c50a
https://pubmed.ncbi.nlm.nih.gov/29581193
https://pubmed.ncbi.nlm.nih.gov/29581193
Autor:
Jennifer M. Robertson, Graham Devereux, E. Devlin, Deborah O'neil, Douglas Fraser-Pitt, Derry K. Mercer
Publikováno v:
EBioMedicine, Vol 2, Iss 10, Pp 1507-1512 (2015)
EBioMedicine
EBioMedicine
Background Cysteamine has recently been shown to have in vitro properties potentially therapeutically beneficial in cystic fibrosis (CF). In this study we investigated the antimicrobial and mucolytic activity of cysteamine against the complex biologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1def26806868d6b04342c322d4230cee
https://doi.org/10.1016/j.ebiom.2015.08.018
https://doi.org/10.1016/j.ebiom.2015.08.018
Autor:
Deborah O'neil, Douglas Fraser-Pitt
Publikováno v:
Future Medicinal Chemistry. 6:1067-1079
Cystic fibrosis (CF) is the most common inherited genetic condition amongst Caucasian ethnicities, affecting 1 in 2500 live births. There remains a significant unmet medical need for more and better therapies for this chronic, degenerative condition,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ddc984e91ddbf3f182b0d2036fb4909
https://doi.org/10.4155/fmc.14.67
https://doi.org/10.4155/fmc.14.67
Autor:
Douglas Fraser-Pitt, Deborah O'neil
Publikováno v:
Future Science OA
Cystic fibrosis (CF) is a heterogeneous multiorgan disease caused by mutations in the CFTR gene leading to misfolding (and other defects) and consequent dysfunction of CFTR protein. The majority of mutations cause a severe CF phenotype, and people wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d0d50c49469df80e61674ab0b6704d2
https://doi.org/10.4155/fso.15.57
https://doi.org/10.4155/fso.15.57
Autor:
Deborah O'neil, Jennifer M. Robertson, Douglas Fraser-Pitt, Catherine Rodger, Cedric Charrier, Nicola Shand, Derry K. Mercer, Aleksandra Kowalczuk
Publikováno v:
Orphanet Journal of Rare Diseases
Background There remains a critical need for more effective, safe, long-term treatments for cystic fibrosis (CF). Any successful therapeutic strategy designed to combat the respiratory pathology of this condition must address the altered lung physiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2015fbbb14b805fa386197df6232529e
https://doi.org/10.1186/s13023-014-0189-2
https://doi.org/10.1186/s13023-014-0189-2
Autor:
Henry Chrystyn, Seonaidh Cotton, E. Devlin, Graham Devereux, Kairen Griffiths, Douglas Fraser-Pitt, Sandra Steele, Deborah O'neil, John Norrie
Publikováno v:
Clinical Drug Investigation
Devereux, G, Steele, S, Griffiths, K, Devlin, E, Fraser-Pitt, D, Cotton, S, Norrie, J, Chrystyn, H & O’Neil, D 2016, ' An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis ', Clinical drug investigation, vol. 36, no. 8, pp. 605-612 . https://doi.org/10.1007/s40261-016-0405-z
Devereux, G, Steele, S, Griffiths, K, Devlin, E, Fraser-Pitt, D, Cotton, S, Norrie, J, Chrystyn, H & O’Neil, D 2016, ' An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis ', Clinical drug investigation, vol. 36, no. 8, pp. 605-612 . https://doi.org/10.1007/s40261-016-0405-z
Cysteamine is licensed for use in nephropathic cystinosis but preclinical data suggest a role in managing cystic fibrosis (CF). This study aimed to determine whether oral cysteamine is absorbed in adult CF patients and enters the bronchial secretions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39037ea03e400be05a07d79fb672c206